参考文献 References
[1] Hyuna S ,Jacques F ,L. R S , et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA: A Cancer Journal for Clinicians,2021.
[2] Chen Y P , Chan A T C , Le Q T ,et al. Nasopharyngeal carcinoma[J].The Lancet, 2019, 394(10192):64-80.
[3] Su S F , Han F , Zhao C ,et al. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy[J]. Chinese journal of cancer, 2011, 30(8):565-73.
[4] Xu T , Tang J , Gu M ,et al. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.[J].Current Oncology, 2013, 20(5):E406-E419.
[5] Teo P T H , Tan N I C , Khoo J .Imaging appearances for recurrent nasopharyngeal carcinoma and post-salvage nasopharyngectomy[J].Clin Radiol, 2013(11).
[6] Yen R F , Hung R L , Pan M H ,et al.18-Fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging[J].Cancer, 2010, 98(2):283-287.
[7] Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy[J].Chinese Journal of Cancer, 2017.
[8] Sun X S , Liang Y J , Jia G D ,et al. Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinoma[J].Oral oncology, 106:104711 [2024-03-11].
[9] Hai-Yan C , Xiu-Mei M , Ming Y ,et al. Effectiveness and Toxicities of Intensity-Modulated Radiotherapy for Patients with Locally Recurrent Nasopharyngeal Carcinoma[J].Plos One, 2013, 8(9):e73918.
[10] Kong L , Wang L , Shen C ,et al. Salvage Intensity Modulated Radiation Therapy (IMRT) for Locally Recurrent Nasopharyngeal Cancer After Definitive IMRT: Treatment Outcomes of a Clinically Distinct Condition in the Modern Era[J].International Journal of Radiation Oncology Biology Physics, 2016, 96(2):E329-E329.
[11] Kong F F , Zhou J , Du C ,et al. Long-Term Survival and Late Complications of Intensity-Modulated Radiation Therapy for Recurrent Nasopharyngeal Carcinoma[J]. International Journal of Radiation Oncology*Biology *Physics, 2018, 102(3):e293-.
[12] Lin R , Slater J D , Yonemoto L T ,et al.Nasopharyngeal Carcinoma: Repeat Treatment with Conformal Proton Therapy—Dose-Volume Histogram Analysis1[J]. radio-logy, 1999, 213(2): 489-494.
[13] Feehan P E , Castro J R , Phillips T L ,et al. Recurrent locally advanced nasopharyngeal carcinoma treated with heavy charged particle irradiation.[J].International Journal of Radiation Oncology Biology Physics, 1992, 23(4):881-4.
[14] Hu J , Huang Q , Gao J ,et al.Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma[J].Cancer, 2020.
[15] Hai-Yan C , Xiu-Mei M , Ming Y ,et al. Effectiveness and Toxicities of Intensity-Modulated Radiotherapy for Patients with Locally Recurrent Nasopharyngeal Carcinoma[J].Plos One, 2013, 8(9):e73918.
[16] William,I,Wei,et al.Surgical salvage of persistent or recurrent nasopharyngeal carcinoma with maxillary swing approach - Critical appraisal after 2 decades[J].Head & Neck, 2010, 33(7).
[17] 徐文瑞,姜彦.复发鼻咽癌挽救性手术方法研究进展[J].山东大学耳鼻喉眼学报, 2019, 33(2):4.
[18] B Y P L A , A Y H W , D J T ,et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial[J]. 2021.
[19] Ho,Wai-kuen,Chan,et al.Early results of robotic assisted nasopharyngectomy for recurrent nasopharyngeal carcinoma[J]. Head & Neck Journal for the Sciences & Specialities of the Head & Neck, 2015.
[20] Zhang L , Huang Y , Hong S .Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial (vol 388, pg 1883, 2016)[J].The Lancet, 2016(10054):388.
[21] Hu J , Bao C , Gao J ,et al.Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results[J].Wiley-Blackwell Online Open, 2018(11).
[22] Guan Y , Liu S , Wang H Y ,et al. Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma[J]. Chinese Journal of Cancer, 2016.
[23] Zhang Y , Zhao L , Huang P ,et al. Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy[J]. Cancer Chemotherapy and Pharmacology, 2012, 70(4):p.611-615.
[24] Ma X , Huang J , Wu X ,et al. Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis[J]. Cancer Biomarkers, 2014, 14(4):267-77.
[25] Jia,Shen, Changling,et al. Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis.[J]. Oncotargets & Therapy, 2019.
[26] Bossi P , Locati L , Licitra L .Emerging tyrosine kinase inhibitors for head and neck cancer[J].Expert Opin Emerg Drugs, 2013, 18(4):445-459.
[27] Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma[J].Cancer Medicine, 2020, 9(5):1721-1732.
[28] Yang Y , Fang W , Ma Y . Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J].Retour au numéro, 2018.
[29] Hsu C , Lee S H , Ejadi S ,et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study[J].Journal of Clinical Oncology, 2017, 35(36):4050-4056.